These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 8692977)

  • 1. Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay.
    Herz AV; Bonhoeffer S; Anderson RM; May RM; Nowak MA
    Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7247-51. PubMed ID: 8692977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral dynamics in hepatitis B virus infection.
    Nowak MA; Bonhoeffer S; Hill AM; Boehme R; Thomas HC; McDade H
    Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4398-402. PubMed ID: 8633078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of drug efficacy and the eclipse phase of the viral life cycle on estimates of HIV viral dynamic parameters.
    Nelson PW; Mittler JE; Perelson AS
    J Acquir Immune Defic Syndr; 2001 Apr; 26(5):405-12. PubMed ID: 11391159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.
    Perelson AS; Neumann AU; Markowitz M; Leonard JM; Ho DD
    Science; 1996 Mar; 271(5255):1582-6. PubMed ID: 8599114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decay characteristics of HIV-1-infected compartments during combination therapy.
    Perelson AS; Essunger P; Cao Y; Vesanen M; Hurley A; Saksela K; Markowitz M; Ho DD
    Nature; 1997 May; 387(6629):188-91. PubMed ID: 9144290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.
    Lewin SR; Ribeiro RM; Walters T; Lau GK; Bowden S; Locarnini S; Perelson AS
    Hepatology; 2001 Nov; 34(5):1012-20. PubMed ID: 11679973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections.
    Sagoe KW; Duedu KO; Ziga F; Agyei AA; Adiku TK; Lartey M; Mingle JA; Arens M
    Ann Clin Microbiol Antimicrob; 2016 Jun; 15(1):38. PubMed ID: 27251610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy.
    Tsiang M; Rooney JF; Toole JJ; Gibbs CS
    Hepatology; 1999 Jun; 29(6):1863-9. PubMed ID: 10347131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Release of virus from lymphoid tissue affects human immunodeficiency virus type 1 and hepatitis C virus kinetics in the blood.
    Müller V; Marée AF; De Boer RJ
    J Virol; 2001 Mar; 75(6):2597-603. PubMed ID: 11222682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of delayed viral production on viral dynamics in HIV-1 infected patients.
    Mittler JE; Sulzer B; Neumann AU; Perelson AS
    Math Biosci; 1998 Sep; 152(2):143-63. PubMed ID: 9780612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The half-life of hepatitis B virions.
    Murray JM; Purcell RH; Wieland SF
    Hepatology; 2006 Nov; 44(5):1117-21. PubMed ID: 17058221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo.
    Markowitz M; Louie M; Hurley A; Sun E; Di Mascio M; Perelson AS; Ho DD
    J Virol; 2003 Apr; 77(8):5037-8. PubMed ID: 12663814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary evidence that azidothymidine does not affect hepatitis B virus replication in acquired immunodeficiency syndrome (AIDS) patients.
    Farraye FA; Mamish DM; Zeldis JB
    J Med Virol; 1989 Dec; 29(4):266-7. PubMed ID: 2621453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Reverse transcriptase inhibitors and the therapy of HIV infection].
    Kraevskiĭ AA; Galegov GA
    Vestn Ross Akad Med Nauk; 1992; (11-12):3-6. PubMed ID: 1284219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and experience with reverse transcriptase inhibitors and protease inhibitors.
    Vella S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S58-61. PubMed ID: 8595511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
    Alvarez-Uria G; Ratcliffe L; Vilar J
    HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absent inhibition of hepatitis B virus replication by azidothymidine in patients chronically coinfected by HIV-1 and HBV.
    Gallian P; De Lamballerie X; Lehucher MP; Dhiver C; Ravaux I
    New Microbiol; 1996 Apr; 19(2):167-9. PubMed ID: 8722313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-generation non-nucleosidic reverse transcriptase inhibitor HBY097 and HIV-1 viral load.
    Rübsamen-Waigmann H; Huguenel E; Paessens A; Kleim JP; Wainberg MA; Shah A
    Lancet; 1997 May; 349(9064):1517. PubMed ID: 9167463
    [No Abstract]   [Full Text] [Related]  

  • 20. Entecavir surprise.
    Hirsch MS
    N Engl J Med; 2007 Jun; 356(25):2641-3. PubMed ID: 17582076
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.